Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
F Ossendorp, E Mengedé, M Camps, R Filius, C J Melief, F Ossendorp, E Mengedé, M Camps, R Filius, C J Melief
Abstract
This study shows that induction of tumor-specific CD4+ T cells by vaccination with a specific viral T helper epitope, contained within a synthetic peptide, results in protective immunity against major histocompatibility complex (MHC) class II negative, virus-induced tumor cells. Protection was also induced against sarcoma induction by acutely transforming retrovirus. In contrast, no protective immunity was induced by vaccination with an unrelated T helper epitope. By cytokine pattern analysis, the induced CD4+ T cells were of the T helper cell 1 type. The peptide-specific CD4+ T cells did not directly recognize the tumor cells, indicating involvement of cross-priming by tumor-associated antigen-presenting cells. The main effector cells responsible for tumor eradication were identified as CD8+ cytotoxic T cells that were found to recognize a recently described immunodominant viral gag-encoded cytotoxic T lymphocyte (CTL) epitope, which is unrelated to the viral env-encoded T helper peptide sequence. Simultaneous vaccination with the tumor-specific T helper and CTL epitopes resulted in strong synergistic protection. These results indicate the crucial role of T helper cells for optimal induction of protective immunity against MHC class II negative tumor cells. Protection is dependent on tumor-specific CTLs in this model system and requires cross-priming of tumor antigens by specialized antigen-presenting cells. Thus, tumor-specific T helper epitopes have to be included in the design of epitope-based vaccines.
Figures
References
- Ostrand-Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol. 1990;144:4068–4071.
- James R, Edwards S, Hui K, Bassett P, Grosveld F. The effect of class II gene transfection on the tumorigenicity of the H-2knegative mouse leukemia cell line K36.16. Immunology. 1991;72:213–218.
- Chen P, Aanathaswamy H. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J Immunol. 1993;151:244–255.
- Yoshimura A, Shiku H, Nakayama E. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4−CD8−T cell receptor-αβ phenotypes generated in CD8-depleted C57BL/6 mice. J Immunol. 1993;150:4900–4910.
- Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 1991;49:281–355.
- Klarnet JP, Kern DE, Okunu K, Holt C, Lilly F, Greenberg PD. FBL-reactive CD8 cytotoxic and CD4 helper T cells recognize distinct Friend murine leukemia virus–encoded antigens. J Exp Med. 1989;169:457–467.
- Hu J, Kindsvogel W, Busby S, Bailey MC, Shi Y, Greenberg PD. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J Exp Med. 1993;177:1681–1690.
- Lilly F, Boyse EA, Old LJ. Genetic basis of susceptibility to viral leukemogenesis. Lancet. 1964;ii:1207–1209.
- Vasmel WLJ, Zijlstra M, Radaszkiewicz T, Leupers CJM, De Goede REY, Melief CJM. Major histocompatibility class II regulated immunity to murine leukemia virus protects against early T- but not late B-cell lymphomas. J Virol. 1988;62:3156–3166.
- Chesebro B, Miyazawa B, Britt WJ. Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Annu Rev Immunol. 1990;8:477–499.
- Iwashiro M, Kondo T, Shimizu T, Yamagishi H, Takahashi K, Matsubayashi Y, Masuda T, Otaka A, Fujii N, Ishimoto A, et al. Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J Virol. 1993;67:4533–4542.
- Vasmel WLE, Sijts EJAM, Leupers CJM, Matthews EA, Melief CJM. Primary virus–induced lymphomas evade T cell immunity by failure to express viral antigens. J Exp Med. 1989;169:1233–1254.
- Plata F, Langlade-Demoyen P, Abastado JP, Berbar T, Kourilsky P. Retrovirus antigens recognized by cytotoxic T lymphocytes activate tumor rejection in vivo. Cell. 1987;48:231–240.
- Sijts AJAM, De Bruijn ML, Ressing ME, Nieland JD, Mengedé EAM, Boog CJ, Ossendorp F, Kast WM, Melief CJM. Identification of an H-2 Kb–presented Moloney murine leukemia virus cytotoxic T lymphocyte epitope that displays enhanced recognition in H-2 Dbmutant bm13 mice. J Virol. 1994;68:6038–6046.
- Chen W, Qin H, Chesebro B, Cheever MA. Identification of a gag-encoded cytotoxic T lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus–induced tumors. J Virol. 1996;70:7773–7782.
- Kast WM, Roux L, Curren J, Blom HJJ, Voordouw AC, Meloen RH, Kolakofski D, Melief CJM. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with an unbound peptide. Proc Natl Acad Sci USA. 1991;88:2283–2287.
- Schulz M, Zinkernagel RM, Hengartner H. Peptide-induced antiviral protection by cytotoxic T cells. Proc Natl Acad Sci USA. 1991;88:991–993.
- Feltkamp MCW, Smits HL, Vierboom MPM, Minnaar RP, De Jongh BM, Drijfhout JW, Ter J, Schegget, Melief CJM, Kast WM. Vaccination with a cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human Papillomavirus type 16-transformed cells. Eur J Immunol. 1993;23:2242–2249.
- Schild H, Norda M, Deres K, Falk K, Rötschke O, Wiesmüller K-H, Jung G, Rammensee H-G. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide. J Exp Med. 1991;174:1665–1668.
- Minev BR, McFarland BJ, Spiess PJ, Rosenberg SA, Restifo NP. Insertion signal sequence fused to minimal peptides elicits specific CD8+T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res. 1994;54:4155–4161.
- Mandelboim O, Vadai E, Fridkin M, Katz-Hillel A, Feldman M, Berke G, Eisenbach L. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med. 1995;1:1179–1183.
- Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJM, Ildstad ST, Kast WM, Deleo AB, Lotze MT. Bone marrow–derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1:1297–1302.
- Sijts AJAM, Ossendorp F, Mengedé EAM, van den Elsen PJ, Melief CJM. Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I binding motif, explains MuLV-type specificity of MCF-directed cytotoxic T lymphocytes. J Immunol. 1994;152:106–116.
- Ljunggren H-G, Kärre K. Host resistance directed selectively against H-2 deficient lymphoma variants. J Exp Med. 1985;162:1745–1759.
- Stukart MJ, Vos A, Melief CJM. Cytotoxic T cell response against lymphoblasts infected with Moloney (Abelson) murine leukemia virus. Methodological aspects and H-2 requirements. Eur J Immunol. 1981;11:251–257.
- Gausepohl, H., M. Kraft, C. Boulin, and R.W. Frank. 1990. Automated multiple peptide synthesis with BOP activation. In Proc. of the 11th American Peptide Symposium. J.E. Rivier and G.R. Marshall, editors. ESCOM, Leiden. 1003–1004.
- Shimonkevitz R, Colon S, Kappler JW, Marrack P, Grey HM. Antigen recognition by H-2–restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J Immunol. 1984;133:2067–2074.
- Bouaboula M, Legoux P, Pességué B, Delpech B, Dumont X, Piechaczyk M, Casellas P, Shire D. Quantitation of cytokine gene expression using a polymerase chain reaction method involving co-amplification with an internal multi-specific control. J Biol Chem. 1992;267:21830–21838.
- Ossendorp F, Eggers M, Neisig A, Ruppert T, Groettrup M, Sijts A, Mengedé E, Kloetzel P, Neefjes J, Koszinowski U, Melief C. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity. 1996;5:115–124.
- Shimizu T, Uenishi H, Teramura Y, Iwashiro M, Kuribayashi K, Tamamura H, Fujii N, Yamagishi H. Fine specificity of a virus-encoded helper T-cell epitope expressed on FBL-3 tumor cells. J Virol. 1994;68:7704–7708.
- Kondo T, Uenishi H, Shimizu T, Hirama T, Iwashiro M, Kuribayashi K, Tamamura H, Fujii N, Fujisawa R, Yamagishi H. A single retroviral gag precursor signal peptide recognized by FBL-3 tumor-specific cytotoxic T lymphocytes. J Virol. 1995;69:6735–6741.
- Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT, Sette A, Grey H. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1994;1:751–761.
- Keene JA, Forman J. Helper activity is required for the induction of cytotoxic T lymphocytes. J Exp Med. 1982;155:768–782.
- Gao X-M, Zheng B, Liew FY, Brett S, Tite J. Priming of influenza virus–specific cytotoxic T lymphocytes in vivo by short synthetic peptides. J Immunol. 1991;147:3168–3173.
- Fayolle C, Deriaud E, Leclerc C. In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+T cell help. J Immunol. 1991;147:4069–4073.
- Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of HIV CD8+CTL in vivo with peptide vaccine constructs. J Immunol. 1994;152:529–556.
- Bennett SRM, Carbone FR, Karamalis F, Miller JFAP, Heath WR. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+T cell help. J Exp Med. 1997;186:65–70.
- Hasenkrug KJ, Brooks DM, Nishio J, Chesebro B. Differing T-cell requirements for recombinant retrovirus vaccines. J Virol. 1996;70:368–372.
- Miyazawa M, Fujisawa R, Ishihara C, Takei YA, Shimizu T, Uenishi H, Yamagishi H, Kuribayashi K. Immunization with a single T helper cell epitope abrogates Friend virus–induced early erythroid proliferation and prevents late leukemia development. J Immunol. 1995;155:748–758.
- Aichele P, Brduscha-Riem K, Zinkernagel RM, Hengartner H, Pircher H. T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med. 1995;182:261–266.
- Toes REM, Blom RJJ, Offringa R, Kast WM, Melief CJM. Functional deletion of tumor-specific cytotoxic T lymphocytes induced by peptide immunization can lead to the inability to reject tumors. J Immunol. 1996;156:3911–3918.
- Toes REM, Offringa R, Blom RJJ, Melief CJM, Kast WM. Peptide vaccination can lead to enhanced tumor outgrowth through specific T-cell tolerance induction. Proc Natl Acad Sci USA. 1996;93:7855–7860.
- Kearney ER, Pape KA, Loh DY, Jenkins MK. Visualization of peptide induced T cell immunity and peripheral tolerance induction in vivo. Immunity. 1994;1:327–339.
- Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol. 1994;68:8056–8063.
- Von Herrath MG, Yokoyama M, Dockter J, Oldstone MBA, Whitton JL. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol. 1996;70:1072–1079.
- Cardin RD, Brooks JW, Sarawar SR, Doherty PC. Progressive loss of CD8+ T cell-mediated control of a γ-herpesvirus in the absence of CD4+T cells. J Exp Med. 1996;184:863–871.
Source: PubMed